Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Scilex's operating income for the twelve months ending Jun 30, 2026 was -$359.19M. For fiscal 2025 it was -$346.01M. The highest annual figure on record is -$35.26M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$346.01M | – |
| FY2024 | Dec 31, 2024 | -$83.40M | – |
| FY2023 | Dec 31, 2023 | -$105.43M | – |
| FY2022 | Dec 31, 2022 | -$50.63M | – |
| FY2021 | Dec 31, 2021 | -$35.84M | – |
| FY2020 | Dec 31, 2020 | -$35.26M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$32.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$111.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$186.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.51M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.47M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.74M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$283.35K | – |
| Q2 FY2021 | Jun 30, 2021 | -$172.14K | – |
| Q1 FY2021 | Mar 31, 2021 | -$165.16K | – |
| Q3 FY2020 | Sep 30, 2020 | -$856 | – |